Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs
Executive Summary
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.